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All purulence is local – epidemiology and
management of skin and soft tissue infections in
three urban emergency departments
Chris Merritt1*, John P Haran2, Jacob Mintzer1, Joseph Stricker1 and Roland C Merchant1
Abstract
Background: Skin and soft tissue infection (SSTIs) are commonly treated in emergency departments (EDs). While
the precise role of antibiotics in treating SSTIs remains unclear, most SSTI patients receive empiric antibiotics, often
targeted toward methicillin-resistant Staphylococcus aureus (MRSA). The goal of this study was to assess the
efficiency with which ED clinicians targeted empiric therapy against MRSA, and to identify factors that may allow
ED clinicians to safely target antibiotic use.
Methods: We performed a retrospective analysis of patient visits for community-acquired SSTIs to three
urban, academic EDs in one northeastern US city during the first quarter of 2010. We examined microbiologic
patterns among cultured SSTIs, and relationships between clinical and demographic factors and management
of SSTIs.
Results: Antibiotics were prescribed to 86.1% of all patients. Though S. aureus (60% MRSA) was the most
common pathogen cultured, antibiotic susceptibility differed between adult and pediatric patients.
Susceptibility of S. aureus from ED SSTIs differed from published local antibiograms, with greater trimethoprim
resistance and less fluoroquinolone resistance than seen in S. aureus from all hospital sources. Empiric antibiotics
covered the resultant pathogen in 85.3% of cases, though coverage was frequently broader than necessary.
Conclusions: Though S. aureus remained the predominant pathogen in community-acquired SSTIs, ED clinicians
did not accurately target therapy toward the causative pathogen. Incomplete local epidemiologic data may contribute
to this degree of discordance. Future efforts should seek to identify when antibiotic use can be narrowed or withheld.
Local, disease-specific antibiotic resistance patterns should be publicized with the goal of improving antibiotic
stewardship.
Keywords: Skin and soft tissue infections, Antibiotic resistance, Antimicrobial stewardship
Background
Emergency department (ED) visits in the US for skin and
soft-tissue infections (SSTIs) have more than tripled in
number in recent decades, [1,2] mirroring the emergence
of community-acquired methicillin-resistant Staphylococcus
aureus (CA-MRSA) [3,4]. Two types of bacterial SSTIs
predominate among ED patients: cellulitis, typically a
non-purulent bacterial skin infection; and abscesses,
characterized by collections of purulent fluid. Though
the current epidemiology of cellulitis is understudied,
the most common circulating strains of CA-MRSA have a
well-described predilection for causing abscesses, and are
the primary pathogens in these purulent SSTIs in many
areas [5].
Prevalence of CA-MRSA varies from region to region.
Most hospitals publish antibiotic susceptibility data from
their own microbiology laboratories. Commonly called
“antibiograms”, these documents are important tools for
use by front-line clinicians in making educated treatment
decisions. However, they typically report aggregate data
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based on bacterial isolates from all sources (blood, skin,
sputum, etc.), and infrequently delineate pathogens based
on the age of the patient or the source of the infection.
Although healthcare exposure appears to remain a risk
factor for drug-resistant infections, ED clinicians are left
with few additional demographic or clinical clues to the
likelihood of resistant organisms in SSTI patients without
exposures. Investigators have also noted differences in
microbiology and treatment of pediatric and adult SSTIs
[6]. Children beyond the neonatal period have been
considered high-risk for CA-MRSA SSTIs relative to
adults, though as the CA-MRSA epidemic has matured,
this distinction has become less clear [7].
Current guidelines for treatment of CA-MRSA infections
do not call for routine antibiotics for adequately drained,
uncomplicated abscesses [8]. Nonetheless, while incision
and drainage (I&D) remains the primary treatment for
abscesses, clinicians prescribe antibiotics for the majority
of these patients and empiric prescription of antibiotics
typically active against CA-MRSA has become routine
[9-13]. In addition, many clinicians provide “double
coverage”, which we define as using two or more anti-
biotics with the intention of effectively treating MRSA,
methicillin-sensitive S. aureus (MSSA) and β-hemolytic
Streptococcus [14,15].
Because antibiotics increase the cost of treatment,
the incidence of adverse medication effects, and – im-
portantly – the selective pressure leading to further
antibiotic resistance, their precise role continues to be
debated [16-21]. Given the inability to predict resistance
based on clinical factors, some discordance between
empiric treatment and pathogen is inevitable. Factors
related to this discordance have not been well studied.
If antibiotic choices are not well targeted, ED patients
with purulent SSTIs may represent a population in whom
antibiotic use could effectively be reduced, decreasing
the selective pressures, cost burdens, and unintended
side effects of these medications.
In this study, our primary objective was to assess –
based on ED antibiotic prescribing choices and culture
results – the efficiency with which ED clinicians targeted
specific pathogens, particularly CA-MRSA, with empiric
antibiotics. Focusing on infections that were most likely to
be community-acquired rather than healthcare-associated,
we assessed whether patient demographics and clinical
features of presumed community-acquired SSTIs might
have led emergency clinicians to prescribe empiric
antibiotic therapy discordant with the susceptibility of
the cultured pathogen or to institute multi-drug “double
coverage”. Because epidemiology and practice patterns are
likely to differ in pediatric and adult patients, we exam-
ined management differences between children and adults
in the ED with presumed-community-acquired SSTIs.
Additionally we sought to determine the prevalent local
microbiologic and practice patterns in ED patients treated
for SSTIs.
Methods
Study design and setting
A retrospective analysis of patient visits for suspected
community-acquired SSTIs to three urban, academic
EDs located in one New England city was performed for
the first quarter of 2010 (January 1 through March 31).
The EDs included an urban adult ED in a large academic
hospital, a pediatric ED in the affiliated academic children’s
hospital, and an academically-affiliated community hospital.
Together, the three EDs care for approximately 200,000
patients per year. This study was approved by the institu-
tional review board of the Lifespan Corporation and was
performed in accordance with the appropriate guidelines
for protection of human subjects and protected health
information.
Study population
Two billing databases containing data for all patient visits
to each of the study EDs – one from the hospitals’ billing
system and one from the physician practice that staffs the
EDs – were combined to maximize catchment. ED visits
for all patients diagnosed with SSTIs were identified from
the combined database using International Classification
of Diseases, 9th Edition (ICD-9) diagnosis codes 680–686
(Infection of Skin and Subcutaneous Tissue). Duplicate
records due to the combination of datasets were elimi-
nated. Repeat visits to the ED for the same SSTI by the
same patient also were eliminated from the study, as were
patients deemed to have likely healthcare-associated
infection by virtue of having been hospitalized or having
surgery within the previous 3 months, or currently residing
in a skilled nursing facility. The latter were identified by
record review from the study hospitals, mention in the
physician chart, or identifying the patient’s address at a
skilled nursing facility.
Study protocol
The protocol adhered to recommendations on the optimal
conduct of retrospective studies for emergency medicine
[22]. A research assistant (RA), blinded to the study objec-
tives, reviewed and abstracted data from the electronic
medical record into a data collection form, recording
demographic, historical and clinical data, and the clinician’s
diagnosis as recorded by the treating clinician (irrespective
of ICD-9 code assigned by billers). A second RA, blinded
to clinical and historical data and using the hospital’s
microbiology laboratory reporting record, recorded whether
or not a culture was ordered in the ED and recorded the
resulting isolates’ antimicrobial susceptibilities. RAs were
trained by the primary investigator (PI), who met regularly
Merritt et al. BMC Emergency Medicine 2013, 13:26 Page 2 of 9
http://www.biomedcentral.com/1471-227X/13/26
with RAs for monitoring of case selection and data
management.
ED visits identified by ICD-9 code that were in fact not
for SSTIs (i.e. coding errors) were excluded following
verification by the PI. The PI reviewed ten percent of
records for data quality and to assess interrater reliability
on three key variables. The kappa statistic for performance
of culture in the ED was 0.81, for performance of I&D was
0.79, and for infection type was 0.90.
Outcome measures
Descriptive measures included MRSA prevalence and
antibiotic prescribing patterns among cultured SSTIs in
the study ED populations. Primary outcomes measured
were (a) the frequency of in vitro activity of ED clinicians’
empiric antibiotic therapy against the cultured isolates
among ED patients with cultured SSTIs, (b) factors
associated with use of discordant antibiotic therapy or
multi-drug antibiotic therapy, and (c) antibiotic resistance
patterns among the most common pathogens identified.
Data analysis
We estimated that 25% of all SSTI patients evaluated
in the ED would undergo culture and that 90% of these
patients would receive antibiotics, with 50% concordance
for MRSA treatment when MRSA was isolated. Given these
assumptions, between 674 and 1199 patient records would
need to be abstracted to arrive at an estimate of antibiotic/
culture discordance with 95% confidence intervals encom-
passing a range of 15 to 20 percentage points.
Antibiotic usage was stratified by culture results, and
age groups were compared using Pearson’s chi-square and
2-sample tests of binomial proportions.
Antibiotics were categorized based on their spectrum
of activity. Anti-staphylococcal antibiotics typically active
against CA-MRSA include trimethoprim-sulfamethoxazole,
tetracycline, doxycycline, clindamycin, rifampin, linezolid or
vancomycin [1,2,13]. Antibiotics with anti-staphylococcal
properties but typically ineffective against CA-MRSA
were categorized as “MSSA antibiotics”: penicillins, first-
generation cephalosporins, macrolides, and fluoroquino-
lones. “Double coverage” describes treatment with two
or more antibiotics with gram-positive coverage. Three
univariable logistic models were created to identify
demographic or clinical variables associated with (1) in vitro
coverage of any organism isolated by the empiric ED anti-
biotic therapy, (2) use of double antibiotic coverage, and
(3) discordance between treatment and culture. In the
third regression model, concordance was defined as
presence of MRSA in culture when any anti-MRSA treat-
ment was prescribed or presence of MSSA in culture when
only anti-MSSA treatment was prescribed. Discordance
is the converse. Data analysis was performed using Stata
(StataCorp, College Station, TX).
Results
The study population
The ICD-9 code search yielded 1,158 separate ED visits
for SSTI, of which 1,094 (94.5%) were initial visits for SSTIs.
The remaining 64 ED visits constituted either return visits
for the same infection or ICD-9 mis-coding. Of the 1,094
ED visits, 160 (14.6%) represented patients with known
healthcare exposure, leaving 936 patients – the study popu-
lation – in whom the SSTI was likely community-acquired.
Table 1 summarizes demographic and clinical character-
istics of the study population, stratified by age group. As
compared to adult community-acquired SSTI patients,
pediatric patients were more likely to be female, non-white,
and insured. In addition, pediatric SSTI patients were more
likely to have a diagnosis other than abscess or cellulitis
(primarily impetigo or paronychia, data not shown). As
compared to adults, more pediatric abscesses occurred
on the buttock (28.8% vs. 15.4%; p < 0.05) and fewer on
the face (6.9% vs. 15.8%; p < 0.05).
ED management of suspected community-acquired SSTIs
Among suspected community-acquired SSTIs, of the ED
patients diagnosed with abscesses, pediatric and adult
patients were equally likely to undergo I&D in the ED
(58.9% and 65.6%; p < 0.29), but microbiologic culture
was ordered more often in the pediatric patients (65.8%
vs. 47.6%; p < 0.005).
The majority of patients with suspected community-
acquired SSTIs were evaluated in the ED and discharged.
Pediatric patients with abscesses were more likely than
adults with abscesses to be admitted to hospital (34.3% vs.
14.5%; p < 0.001).
Antibiotic use
Antibiotics (whether intravenous (IV) or oral, used in the
ED or prescribed at discharge, or any combination of these)
were prescribed to 86.1% of the 936 ED patients with
suspected community-acquired SSTIs (94% of those with
cellulitis vs. 78.4% of those with abscess; p < 0.0001). For
patients with cellulitis, 93.9% of adult and 94.1% of
pediatric patients were prescribed antibiotics (p < 0.97);
for those with an abscess, 76.9% of adult and 84.9% of
pediatric patients were prescribed antibiotics (p < 0.14);
and for all other suspected community-acquired SSTIs,
73.6% of adult and 85.3% of pediatric patients were
prescribed antibiotics (p < 0.20).
Overall, 38.2% of SSTI patients (88.6% of admitted
patients and 15.7% of discharged patients) received IV
antibiotics in the ED, more frequently in adults than in
children (40.4% vs. 29.8%; p < 0.009). The most commonly
prescribed IV antibiotics for adults were vancomycin
(24.9%), ampicillin/sulbactam (11.4%), and, cefazolin (7.9%),
and for children were clindamycin (15.7%), cefazolin (5.8%),
and ampicillin/sulbactam (4.7%). Adult patients were more
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likely than pediatric patients to receive IV vancomycin
(24.9 vs. 1.6%; p < 0.001) and ampicillin/sulbactam (11.4%
vs. 4.7%; p < 0.007), but were less likely than pediatric pa-
tients to receive IV clindamycin (4.6% vs. 15.7%; p < 0.001).
Among discharged patients, trimethoprim-sulfameth-
oxazole (TMP-SMX), clindamycin, and cephalexin were
prescribed commonly. 25.3% of all SSTI patients received
an oral antibiotic in the ED, and 80.8% of patients dis-
charged received an antibiotic prescription. Adult SSTI
patients were more likely than pediatric SSTI patients to
be prescribed oral TMP-SMX (59.1% vs. 37.2%; p < 0.001)
at ED discharge. Of those prescribed TMP-SMX, adults
were more likely than children to be also prescribed oral
cephalexin (53.8% vs. 34.5%; p < 0.001).
Microbiologic data
Table 2 summarizes the results of microbiologic cultures
by age group among ED patients with cultured infections.
S. aureus comprised the majority of culture isolates, and
was more common in pediatric patients, while mixed flora
was more common among adults than among children.
Of S. aureus isolated from CA-SSTIs, 60.4% was catego-
rized as MRSA, with similar proportions in adults and
children (60.9% vs. 59.2%; p < 0.84).
Table 3 depicts the antibiotic susceptibilities among
S. aureus isolated from presumed community-acquired
purulent infections, comparing the resistance in these
ED-acquired SSTI cultures against the resistance reported
for MRSA and MSSA on the antibiogram distributed by
the hospitals’ microbiology laboratory for S. aureus from
all sources in 2010.
Discordance of antibiotic therapy with culture results
Table 4 compares antibiotic treatment with culture results
among SSTIs for which both antibiotics were prescribed
and cultures obtained. Clinicians using single antibiotics
(anti-MRSA [Table 4A] or anti-MSSA [Table 4B]) used
Table 1 Demographic and clinical characteristics of ED
patients with community-acquired Skin and Soft-tissue
infections (SSTIs) by age group
Demographic and
clinical characteristics
Pediatric
(age < 18)
Adult
(age ≥18)
p-value
n = 191 n = 745
% % p<
Median age in years (IQR) 7 (0–17) 39 (18–89) p < 0.001
Gender p < 0.02
Male 47.6 57.2
Female 52.4 42.8
Ethnicity/race p < 0.001
White 52.9 67.9
Black 22.0 17.6
Hispanic/Other 25.1 14.5
Health insurance status p < 0.001
Private 36.6 33.4
Governmental 44.5 31.3
Both Private and Governmental 8.9 7.0
Uninsured 10.0 28.3
Infection type p < 0.001
Abscess 38.3 41.9
Cellulitis 44.0 51.0
Furuncle 0.5 0.5
Carbuncle 0.5 0.0
Ulcer 0.5 0.3
Other 16.2 6.3
Previous assessment
for this infection
28.3 25.8 p < 0.5
Previous antibiotic
treatment for this infection
20.9 18.2 p < 0.4
IQR = interquartile range.
Table 2 Microbiologic culture results from emergency
department (ED) patients with community-acquired skin
& soft tissue infections
Culture result Pediatric n = 70%
(% pre-treated)
Adult n = 241%
(% pre-treated)
No Growth 7.4 9.6
(80) (25)
Staphylococcus aureus 72.1 52.6
(20.4) (21.8)
MRSA 44.3 31.1
MSSA 27.8 21.5
Group B Streptococcus 1.5 3.8
(0) (12.5)
Group A Streptococcus 7.4 1.4
(0) (0)
Escherichia coli 0 1.9
(0)
Pseudomonas aeruginosa 0 1.4
(0)
Klebsiella species 0 0.5
(0)
Mixed Skin Flora 3 16.8
(0) (11.4)
Other Mixed Floraa 0 2.4
(20)
Other 8.6 9.6
(33.3) (15)
aIncludes Mixed Oral Flora and Mixed GI Flora.
%Pre-treated depicts the percentage of patients identified as having received
prior antibiotic treatment for the infection in question.
MRSA =methicillin-resistant S. aureus, MSSA =methicillin-sensitive S. aureus.
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monotherapy that accurately targeted the resultant cul-
tured pathogen accurately 39.3% of the time (ranging
from 35-52% depending on age and treatment strategy).
Cultured SSTIs from 100% of pediatric patients and
67.8% of adult patients treated with multi-drug “double
coverage” (Table 4C) grew only Staphylococcus.
Table 5 displays the univariable logistic regression
analyses investigating demographic and clinical correlates
of coverage of the resultant pathogen with the chosen
antibiotic regimen, “double coverage” antibiotic usage,
and discordance of empiric MRSA therapy (use of anti-
MRSA antibiotics in the absence of MRSA, or vice versa).
Table 3 Antibiotic Resistance Among Staphylococcus aureus Isolated from skin and soft tissue infections (SSTIs) in the
emergency department
MSSA MRSA
ED Samples
(n = 76; 56 Adult)
Antibiogram
(n = 619)
ED Samples
(n = 101; 70 Adult)
Antibiogram
(n = 473)
Drug Pediatric%
resistant
Adult%
resistant
Total%
resistant
Pediatric%
resistant
Adult%
resistant
Total%
resistant
Ciprofloxacin 0% 2.9% 14% 19.3% 24.5% 61%
Clindamycin 0% 14.7 NR 9.7% 4.1% NR
Erythromycin 28.6% 41.2% 39% 87.1% 100% 92%
Gentamicin 0% 0% 0% 0% 0% 1%
Levofloxacin 0% 2.9% 13% 19.3% 22.5% 60%
Moxifloxacin 0% 2.94% NR NR NR NR
Oxacillina 0% 0% 0% 100% 100% 100%
Penicillin 85.7% 82.3% NR 100% 100% NR
Tetracycline 14.3% 5.9% 5% 0% 0% 2%
TMP/SMX 35.7% 2.9% 1% 0% 0% 1%
Vancomycin 0% 0% 0% 0% 0% 0%
Inducible Clindamycin Resistance 0% 14.7% NR 3.2% 4.1% NR
Bolded pairs achieved statistical significance (p < 0.05) in chi-square analysis.
MSSA =methicillin-sensitive S. aureus; MRSA =methicillin-resistant S. aureus; TMP/SMX = Trimethoprim/Sulfamethoxazole; NR = Not Reported
aOxacillin resistance defines MRSA vs. MSSA in this clinical laboratory.
Table 4 Empiric antibiotic treatment and targeted organisms in microbiologic culture
A. Culture results
Pediatric Adult
MRSA% Other result% MRSA% Other result%
Anti-MRSA therapy only 52.6 47.4 34.5 65.5
B
Culture results
Pediatric Adult
MSSA% Other result% MSSA% Other result%
Anti-MSSA therapy only 37.5 72.5 35 65
C.
Culture results
Pediatric Adult
MRSA% MSSA% Other result% MRSA% MSSA% Other result%
Double Coverage 62.5 37.5 0.0 44.3 21.5 34.2
MSSA =methicillin-sensitive S. aureus; MRSA =methicillin-resistant S. aureus.
NB : Patients (63 pediatric, 189 adult) with skin and soft tissue infections (SSTIs) that were cultured in the ED and who received antibiotics are shown, with
pediatric and adult patients considered separately. Tables are separated by empiric therapy given and the culture result targeted. 4A: Patients who were treated
with empiric anti-MRSA antibiotics only. 4B: Patients who were treated with empiric anti-MSSA antibiotics only. 4C: Patients who were treated with double
coverage (treatment with two or more antibiotics with gram-positive coverage).
Anti-MRSA antibiotics include antibiotics typically active against community-acquired (CA-) MRSA: trimethoprim-sulfamethoxazole, tetracycline, doxycycline,
clindamycin, rifampin, linezolid or vancomycin. Anti-MSSA antibiotics include anti-staphylococcal antibiotics typically ineffective against CA-MRSA (penicillins,
cephalosporins, macrolides, fluoroquinolones).
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Patients who underwent I&D were more likely to receive
antibiotics that covered the resultant pathogen than those
who did not undergo the same procedure in the ED.
Patients admitted to the hospital were more likely to
receive antibiotics in the ED to which the resultant
pathogen was susceptible than those discharged home.
Age group was strongly associated with treatment with
two or more antistaphylococcal antibiotics, with adult
patients more likely than pediatric patients to receive such
multiple antibiotic coverage. Black patients were less likely
than non-black patients to receive multi-drug coverage.
However, when age and race were considered jointly as
correlates, only adult age remained associated with greater
“double coverage” usage.
There were no demographic or clinical factors identified
in association with discordance between presence or
absence of empiric anti-MRSA antibiotic therapy and the
presence or absence of MRSA among those undergoing
culture and receiving antibiotics.
Discussion
Emergency clinicians routinely make decisions for SSTIs
based on incomplete information; treatment guidelines
remain vague regarding when antibiotics are indicated,
Table 5 Logistic models to identify factors associated by univariate analysis with coverage of the isolated organism by
the antibiotic prescribed (A), treatment with multiple antibiotics (“double coverage”) (B), and discordant anti-mrsa
therapy (C)
Variable (A) Coverage of the organism
isolatedΔ (n=156) or (95%C.I.)
(B) Double coverage
(n = 804) or (95%C.I.)
(C) Discordant anti-mrsa
therapy (n = 181) or (95%C.I.)
Age group (adult vs. pediatric) 1.92 (0.78-4.76) 5.60 (3.39-9.25) 1.63 (0.82-3.23)
Infection Location
Hand Ref. Ref. Ref.
Other extremity 1.71 (0.45-6.44) 1.37 (0.87-2.18) 1.16 (0.41-3.25)
Buttock *** 1.07 (0.55-2.11) 1.00 (0.28-3.54)
Trunk 2.31 (0.5-10.67) 1.00 (0.56-1.78) 0.64 (0.22-1.87)
Head 0.62 (0.1-3.66) 1.15 (0.44-2.96) 4.00 (0.40-39.83)
Face 4.92 (0.49-49.61) 0.95 (0.54-1.68) 0.46 (0.13-1.59)
Genitalia 0.31 (0.02-6.11) 1.07 (0.30-3.81) 0.67 (0.04-12.27)
Multiple Locations 1.23 (0.11-14.42) 1.07 (0.45-2.54) 0.67 (0.08-5.75)
Previous assessment for this infection 1.27 (0.4-4.02) 0.85 (0.60-1.20) 0.86 (0.42-1.79)
Previous antibiotic treatment for this infection 4.13 (0.53-32.28) 0.81 (0.54-1.22) 0.45 (0.19-1.07)
Disposition (hospital admission) 2.78 (1.12-6.89)* 0.99 (0.73-1.35) 0.66 (0.33-1.32)
I&D performed 4.47 (1.71-11.65)* 1.07 (0.77-1.47) 0.87 (0.47-1.60)
Culture performed N/A 1.37 (1.00-1.87) N/A
Gender
Male Ref. Ref. Ref.
Female 0.92 (0.38-2.24) 0.75 (0.56-1.00) 0.82 (0.45-1.47)
Ethnicity/race
White Ref. Ref. Ref.
Black 1.58 (0.49-5.05) 0.65 (0.43-0.97)* 0.89 (0.41-1.89)
Hispanic/Other 5.62 (0.71-44.27) 0.72 (0.48-1.09) 1.06 (0.46-2.42)
Health insurance status
Private Ref. Ref. Ref.
Governmental 1.31 (0.41-4.19) 0.94 (0.66-1.34) 0.85 (0.40-1.77)
Both private and Governmental 0.11 (0.02-0.5)* 0.80 (0.45-1.43) 1.94 (0.36-10.50)
None 1.63 (0.44-5.98) 1.23 (0.84-1.81) 0.69 (0.33-1.47)
Δexcludes cultures with no growth or mixed flora and patients not treated with antibiotics.
* denotes statistically significant result.
*** variable had perfect prediction in the model.
NB: Three univariable logistic models were created to identify demographic or clinical variables associated with (A) coverage of the organism isolated by the
empiric ED antibiotic therapy, (B) use of multiple antibiotics as empiric therapy (“double coverage”), and (C) discordance between use of anti-MRSA antibiotics and
presence of MRSA as identified by microbiologic culture. In the third regression model, concordance was defined as presence of MRSA in culture when any
anti-MRSA treatment was prescribed or presence of MSSA in culture when only anti-MSSA treatment was prescribed.
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information about local epidemiology is often incomplete,
and microbiologic data for individual patients are not
available in the time frame of an ED visit.
In this study, we identified a population of ED patients
with presumed community-acquired SSTIs in whom S.
aureus remained the most common pathogen and for
whom antibiotic prescription remained high. Despite the
prevalence of S. aureus as the target of therapy, antibiotic
regimens varied significantly. Among patients who under-
went culture and received antibiotics, discordance between
the choice to treat empirically with anti-MRSA antibiotics
and the presence or absence of the resistant organism in
culture was high; patients were often treated narrowly for
MRSA infections, or broadly for MSSA infections.
The microbiology of skin abscesses does not appear to
be uniform; resistance patterns from our sample differed
between children and adults. Increased resistance to
TMP/SMX – among the most commonly-used antibiotics
in SSTIs – was noted, particularly in MSSA isolated from
children. Though the number of pediatric MSSA infections
was a small proportion of the total number of patients, 20
of the 49 S. aureus cultures from children were MSSA. The
implications of this finding are not immediately clear, but
highlight the importance of (a) knowledge of local disease
epidemiology, and (b) performance of surveillance cultures
in at least some subset of ED patients treated for SSTIs.
This epidemiologic surveillance is important in monitoring
infections treated in the ED, and may identify emerging
resistance before it becomes broadly apparent.
Importantly, differences in disease epidemiology were
not reflected in the antibiogram distributed by the hospitals’
microbiology laboratory. S. aureus from SSTIs had greater
TMP/SMX resistance and less fluoroquinolone resistance
than reflected in the antibiogram. The resistance patterns
reflected in composite antibiograms may mask important
differences in pathogens’ behavior in SSTIs, since the anti-
biogram does not distinguish between pathogens isolated
from blood, sputum, or other sources. The strains of S.
aureus that cause purulent SSTIs differ from those that
cause other invasive infections, and this may not be clear
when microbiologic data is viewed in the aggregate.
Laboratories should consider reporting disease-specific
antibiotic resistance data, as this more granular data could
drive therapeutic decision-making.
None of the demographic or clinical factors in our
logistic model correlated choice of empiric anti-MRSA
therapy with the presence or absence of MRSA in culture
in our sample of patients who underwent culture and
received antibiotics. Using prescribing behavior as a
proxy for clinician beliefs, there did not appear to be
specific factors interpreted by ED clinicians as being
predictive of a particular pathogen’s antibiotic susceptibility.
However, those patients who were admitted to the hospital
or who underwent I&D in the ED were more likely to
receive antibiotic therapy in the ED to which the resultant
cultured organism was susceptible, suggesting that those
patients deemed to be more ill or to require an invasive
procedure were more likely to receive broader antibiotic
therapy.
Use of “double coverage” – two or more antibiotics,
typically TMP-SMX plus cephalexin – was prevalent, and
was likely intended to address perceived deficiencies of
single-agent treatment with TMP-SMX in treating strepto-
cocci. However, cultures from the large majority of patients
treated with “double coverage” yielded staphylococci alone,
suggesting that empiric anti-streptococcal treatment may
not be necessary. When viewed from an antibiotic steward-
ship perspective, “double coverage” doubles the exposure
to antibiotics and may drive resistance without leading to
improved therapy.
Only age group was reliably associated with use of
“double coverage” in our logistic model; children were
less likely to receive multiple antibiotics. Otherwise, the
choice appears to be one of clinician discretion. Given that
most isolates even from adult patients yielded staphylo-
cocci, and that I&D alone is sufficient therapy for most
uncomplicated abscesses, use of a single antibiotic – chosen
using local epidemiologic data, where available – is
warranted if antibiotics are deemed necessary.
The clinician can opt not to treat uncomplicated, small
purulent infections with antibiotics if adequate I&D is
performed. This is increasingly supported by the evidence
and in recent guidelines for treatment of CA-MRSA infec-
tions, and is not likely to decrease treatment failure or in-
crease selective pressures toward antibiotic resistance [8].
We acknowledge several limitations to the current study.
Its retrospective nature limits the data to that which could
be collected from the medical record. However, we believe
that we have adhered to high standards for retrospective
ED studies [22,23]. We could not directly assess the ED
clinicians’ intention when choosing which SSTIs to treat
with which antibiotics, and could only infer from those
choices. Medical records rarely described SSTIs in detail,
omitting the degree of cellulitis adjacent to an abscess.
We attempt to account for this by limiting our analysis
to the “accuracy” of antibiotic choices without inferring
the clinicians’ specific intent.
Our findings are significant in that they reflect the
current state of antibiotic use and overuse. We were unable
to correlate the choices of empiric antibiotics provided
in the study EDs with any of the demographic or clinical
variables studied. Clinicians, given the state of epidemio-
logic data and clinical tools available during the study
period, had insufficient information to predict the sus-
ceptibility of an SSTI pathogen at the time that empiric
therapy was chosen. If a clinician could (a) determine
which purulent SSTIs require antibiotic treatment, and
(b) estimate the narrowest effective antibiotic coverage
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using local disease-specific data or other tools, antibiotic
overuse could be limited.
Future efforts in ED management of purulent SSTIs
may focus on determining which patients benefit from
antibiotic therapy, outcomes in patients treated without
antibiotics, and ensuring that adequate I&D can be
performed in the ED setting. PCR and other rapid-MRSA-
testing technologies are becoming widely available, [24]
though these newer technologies have not yet been widely
studied in the clinical setting.
Conclusion
Staphylococcus aureus is the predominant pathogen in
community-acquired purulent SSTIs in the ED, and most
patients evaluated for these infections received antibiotics
even after I&D. Although antibiotic use, including multi-
drug “double coverage”, remained common in the sample
studied, empiric antibiotics used varied widely, and were
poorly targeted toward the causative organisms, all of
which represents an opportunity to reduce antibiotic
overuse. Local epidemiologic data is critical to the
decision-making of ED clinicians, and laboratories should
consider reporting disease-specific antibiograms. Future
efforts to identify SSTIs in which antibiotic use, particu-
larly anti-MRSA therapy, is indicated could further reduce
antibiotic overuse and improve antibiotic stewardship.
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